Example: Cetylpyridinium chloride
Direct compression of lozenges
Pharma Ingredients & Services. Welcome to more opportunities.
ExcipientsCustom Synthesis | | Active Ingredients Excipients
ExExActConcepts
This formulation concept effectively combines
Convenient manufacturing based on direct compression è one-step tableting and trouble-free processing
Direct compression reduces
the number of process steps
and thereby helps to decrease
process time and cost.
Direct compression
Hardness throughout the
handling of tablets is often of
great importance. This applies
to handling through a patient
as well as handling in preced-
ing work stages, e.g. coating.
High strength & low friability
Lozenges are mainly applied
in the local treatment of soar
throats. The drug remains in
the oral cavity for an extended
period of time and therefore
has a local effect there.
Benefi ts through lozenges
Task:Produce a lozenge by direct compression
Ludipress® LCEan excipient for direct compression,
shows excellent compression properties:
• High compressibility
• Excellent fl owability
• Low lubricant sensitivity
• Outstanding blending behavior with actives
Lozenges
Chewable tablets
Effervescent tablets
Sublingual tablets
Modifi ed release tablets
SEM Ludipress® LCE
This excipient is specially suitable for
Concept:A BASF excipient
60.9 μm
Example formulationLozenge with Cetylpyridinium chlorid
Composition Parameter setManufacturing instructions
Pass all ingredients through a sieve
(0.8 mm sieve).
Blend all ingredients for 10 minutes
using a Turbula blender.
Compress mixture into tablet.
Ingredient Function
420 mg
Quantity [%]
Cetyl-pyridi-nium chloride
API 2.5
Ludipress® LCE
Filler, binder
370.0
Kollidon® 90 F
Binder 20.0
PEG 6000 powder
Lubricant 20.0
Aspartame Sweetener 1.5
Menthol Flavor 6.0
Preparation of lozenge Compression
Tablet press
Korsch PH106
(rotary press
with compres-
sion research
system)
Punch10 mm
diameter
Compression force 30 kN
* Tablet hardness dependent
on compression force
03_120811e-0
0
BASF SEPharma Ingredients & ServicesChemiestraße 22
68623 Lampertheim
Germany
Phone: +49 621 60 - 0
www.pharma-ingredients.basf.com
Disclaimer
The data contained in this publication are based on our current knowledge and experience. In view of the many factors that may affect processing and application of our
product, these data do not relieve processors from carrying out their own investigations and tests; neither do these data imply any guarantee of certain properties, nor the
suitability of the product for a specifi c purpose. Any descriptions, drawings, photographs, data, proportions, weights etc. given herein may change without prior informa-
tion and do not constitute the agreed contractual quality of the product. It is the responsibility of the recipient of our products to ensure that any proprietary rights and
existing laws and legislation are observed. (01 / 2012) ® = registered trademark of BASF SE
Analytical results
Crushing strength 224 N
Disintegration time* 28:02 min:s
Standard deviation of mass 1.2%
* Disintegration time can be adjusted by chan-
ging compression force and incorporation of
a high molecular weight polymer binder
Apparatus: Ph.Eur. 7.0, TEST A